Previous 10 | Next 10 |
home / stock / pmn:cc / pmn:cc news
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neur osciences Inc. (TSX: PMN) (NASDAQ: PMN ) (“ProMIS” or the “Corporation”) is pleased to announce that it has completed its continuance (the “ Continuanc...
Company to voluntarily delist from the Toronto Stock Exchange (TSX) Last trading day on TSX will be July 21, 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company fo...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neur osciences Inc. (TSX: PMN) (NASDAQ: PMN ) , a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerativ...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMNRFXF) (“ ProMIS ” or the “Corporation”) is issuing this release to correct the URL required to virtually access the Cor...
Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s disease Presented preclinical data supporting target identification and candidate differentiation across pipeline of antibody therapeutics at international neuro...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 08, 2023 (GLOBE NEWSWIRE) -- In pre clinical studies, PMN310 demonstrated the abilit y to selectively target and protect against pathogenic Aβ oligomers The IND clearance of PMN310 in the...
Findings support Aβ vaccine candidate consisting of conformational B cell epitope of Aβ oligomers conjugated to a carrier protein as a potential strategy for preventing Alzheimer’s disease progression TORONTO, Ontario and CA...
Lead therapeutic candidate for Alzheimer’s disease, PMN310, demonstrate d selective binding and protection against toxic amyloid-beta oligomers Preclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP TORONTO, Ontario and CAMBRIDGE, Ma...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as...
News, Short Squeeze, Breakout and More Instantly...
Promis Neurosciences Inc. Company Name:
PMN:CC Stock Symbol:
TSXC Market:
CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such ...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer&...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.(Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer...